Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 31;9(1):104. doi: 10.3390/jcm9010104

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Redaporfin-PDT induces a strong neutrophilia, which contributes significantly for the treatment efficacy. (A) Relative percentage of blood leukocyte evaluated by flow cytometry at different time points after redaporfin-PDT. (B) Relative percentage of neutrophils (CD45⁺, GR1⁺ and CD11b⁺) evaluated by flow cytometry 24 h and seven days after redaporfin-PDT. Bars are the mean ± SD of six mice. No symbol p > 0.05; * p < 0.05; ** p < 0.01; *** p < 0.001. (C) Survival curve of mice bearing CT26.WT tumours treated with redaporfin-PDT in normal conditions or upon neutrophils depletion using Ly6G/Ly6C monoclonal antibodies. (D) Tumour growth represented individually for each mouse (6–11 mice per group). Survival curve statistics by LogRank (Mantel-Cox) test. No symbol: p > 0.05; * p < 0.05.